Home » Market News » DirectorsTalk Highlights » Trackable Smart Drug Delivery System for Cancer Treatment
Avacta Group Plc

Trackable Smart Drug Delivery System for Cancer Treatment

Precise targeting and controlled drug release can significantly enhance the therapeutic efficacy of cancer treatment. Trackable smart drug delivery systems have gained attention in the past decade because they can be visualised by one or more imaging technologies through their distinct physical properties. However, it is still difficult to achieve precise drug delivery because such systems usually rely on a single imaging system that cannot clearly distinguish the drug carrier system from the surrounding tissue and the targeted lesion.

Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.